Literature DB >> 25745537

Melanoma: Molecular Pathogenesis and Therapeutic Management.

Yuxin Liu1, M Saeed Sheikh1.   

Abstract

Malignant melanoma remains one of the fastest growing cancers worldwide. Although the primary cutaneous melanoma can be managed by surgery, the advanced metastatic melanoma cannot be managed by surgery alone and thus, requires better therapeutic approaches. In view of high mortality rates due to metastatic melanoma, better understanding of the molecular pathogenesis of malignant melanoma is urgently needed. Such information is expected to prove very valuable in early detection of potential metastatic lesions and developing newer therapeutic approaches in order to better manage this malignancy. This article reviews the available information on the molecular changes associated with malignant melanoma and discusses the potential of such information in facilitating the development of newer anti-melanoma therapeutics. Current state of knowledge and the future of traditional and newly approved anti-melanoma therapeutics are also discussed.

Entities:  

Keywords:  BRAF; Cobimetinib; Dabrafenib; Melanoma; Trametinib; Vemurafenib

Year:  2014        PMID: 25745537      PMCID: PMC4346328     

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  125 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  PI3-kinase subunits are infrequent somatic targets in melanoma.

Authors:  John A Curtin; Mitchell S Stark; Daniel Pinkel; Nicholas K Hayward; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2006-04-13       Impact factor: 8.551

3.  An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

Authors:  Keiran S M Smalley; Rooha Contractor; Nikolas K Haass; Angela N Kulp; G Ekin Atilla-Gokcumen; Douglas S Williams; Howard Bregman; Keith T Flaherty; Maria S Soengas; Eric Meggers; Meenhard Herlyn
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

4.  Clinical aspects of familial cutaneous malignant melanoma.

Authors:  M A Tucker; S J Bale
Journal:  Semin Oncol       Date:  1988-12       Impact factor: 4.929

5.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

6.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

Review 7.  Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

Authors:  Steven J O'Day; Omid Hamid; Walter J Urba
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

8.  The Queensland Familial Melanoma Project: study design and characteristics of participants.

Authors:  J F Aitken; A C Green; R MacLennan; P Youl; N G Martin
Journal:  Melanoma Res       Date:  1996-04       Impact factor: 3.599

9.  Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.

Authors:  L Liu; N J Lassam; J M Slingerland; D Bailey; D Cole; R Jenkins; D Hogg
Journal:  Oncogene       Date:  1995-07-20       Impact factor: 9.867

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  43 in total

Review 1.  Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.

Authors:  Sohita Dhillon
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493

2.  Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study.

Authors:  Syed Mohammad Husain Rizvi; Bjarte Aagnes; Hallvard Holdaas; Einar Gude; Kristin Muri Boberg; Øystein Bjørtuft; Per Helsing; Torbjørn Leivestad; Bjørn Møller; Petter Gjersvik
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

Review 3.  Exosome application in tumorigenesis: diagnosis and treatment of melanoma.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Nafiseh Jafari; Maryam Mehdi; Fatemeh Alavi; Mona Daraei; Niloufar Mohammadkhani; Anna-Lena Mueller; Aranka Brockmueller; Mehdi Shakibaei; Zahra Payandeh
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

4.  Potential Anticancer Agents against Melanoma Cells Based on an As-Synthesized Thiosemicarbazide Derivative.

Authors:  Paweł Kozyra; Agnieszka Korga-Plewko; Zbigniew Karczmarzyk; Anna Hawrył; Waldemar Wysocki; Michał Człapski; Magdalena Iwan; Marta Ostrowska-Leśko; Emilia Fornal; Monika Pitucha
Journal:  Biomolecules       Date:  2022-01-18

5.  Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.

Authors:  R R Maniyar; S Chakraborty; T Jarboe; R Suriano; M Wallack; J Geliebter; R K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

Authors:  Anthony W Tolcher; Razelle Kurzrock; Vincente Valero; Rene Gonzalez; Rebecca S Heist; Antoinette R Tan; Julie Means-Powell; Theresa L Werner; Carlos Becerra; Chenxi Wang; Cathrine Leonowens; Shanker Kalyana-Sundaram; Joseph F Kleha; Jennifer Gauvin; Anthony M D'Amelio; Catherine Ellis; Nageatte Ibrahim; Li Yan
Journal:  Cancer Chemother Pharmacol       Date:  2020-02-15       Impact factor: 3.333

Review 7.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 8.  MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein.

Authors:  Anjan K Pradhan; Santanu Maji; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 9.  The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma.

Authors:  Elizabeth L Thompson; Jiayi J Hu; Laura J Niedernhofer
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

Review 10.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.